Hong Kong registered charity no 91/10374

|
|
Help Celebrate a Milestone
- It's a remarkable achievement: and one that many thought would never be possible.
Poliomyelitis (polio) is a highly infectious disease caused by poliovirus that invades the nervous system and can cause permanent paralysis.
There are three serotypes of poliovirus (1, 2, and 3). Immunity to one serotype does not protect against the other serotypes.
Wild poliovirus type 2 has been eradicated and cases of type 3 fell 92 percent from 2009 to 2010.
Polio affects children mainly below the age of five, but immune and partially immune adults can still be affected by the disease.
Although the most visible sign of polio is paralysis; only one percent of the effects of the disease is likely to be paralysis.
Polio has no symptoms and can spread widely before paralysis is visible. Those affected by polio are often not aware that they have the disease.
It is passed through person to person contact.
The disease has been eliminated in most countries in the world.
There is no treatment for polio. However, the disease can be prevented through vaccination and simple health interventions.
The world stands on the brink of eradicating polio - a debilitating disease that pulls vulnerable individuals deeper into poverty. Over 2.5 billion children have been vaccinated since 1988 and the number of polio cases per year is down by 99 percent.
Global collaboration over three decades has reduced cases by 99% - bringing the end within reach. But crucial vaccination work is being constrained by a global funding gap, threatening the prospect of eradication.
There are two types of vaccines against polio—oral polio vaccine (OPV) and inactivated polio vaccine (IPV) delivered via injection.
OPV contains an attenuated (weakened) virus that can mutate into vaccine-derived poliovirus (VDVP) that can circulate and cause polio infections in a community.
VDPVs will continue unless global community makes the transition to IPV after wild poliovirus is eradicated.
OPV can also result in vaccine-associated paralytic polio (VAPP), although this is rare, occurring once for every 2.7 million first doses of the vaccine.
Most wealthy countries use IPV, but because the current price (>$3/dose) is out of reach for low- and middle-income countries, they rely on OPV ($.13 -.17/dose).
To complete eradication and to ensure protection post-eradication, new tools are needed:
![]()
Lower cost OPV for maintaining population immunity, for stamping out pockets of endemic wild poliovirus transmission, and for controlling outbreaks.
![]()
Much more affordable IPV to contain and end VDPVs and sustain population immunity post eradication.
![]()
Affordable IPV-containing pediatric combination vaccines for future birth cohorts in low-income countries.
